the fact that Helicobacter pylori is one of the major causes of gastric cancer.
H. pylori Infection and Risk of Gastric Cancer
H. pylori is a Gram-negative bacterium that selectively colonizes the gastric mucosa. Infection rates vary, with a mean of 20-40% in developed countries and 60-80% in developing countries. 4 After infection, the bacterium persists for the lifetime of the host. Prolonged infection may lead to chronic gastritis, peptic ulcer, gastric cancer, and/or mucosa-associated lymphoid tissue (MALT) lymphoma. 1 On the basis of epidemiologic studies, the World Health Organization classified H. pylori as a class I (definite) carcinogen in humans in 1994. 4 Several meta-analyses have shown a strong and consistent association between H. pylori infection and noncardiac gastric cancer (Table 1) . [5] [6] [7] [8] An updated consensus has indicated that chronic atrophic gastritis caused by H. pylori is the major precursor of gastric cancer. 9 In a recent study, the attribution fraction of noncardiac gastric cancer was 74% in developed countries and 78% in developing countries. These percentages represented 592,000 cases, or 5.5% of all cancers. 10 In addition to epidemiologic observations, data from animal studies have solidified the causal relationship between H. pylori infection and gastric cancer. 11 Furthermore, biological studies have clarified the underlying molecular mechanisms. [12] [13] [14] [15] To sum up, epidemiologic, animal and biological studies have provided consistent evidence to confirm the role of H. pylori infection in gastric carcinogenesis. 16 
Health Economic Models to Estimate the Efficacy of H. pylori Eradication
The strong link between H. pylori infection and gastric cancer presents a unique opportunity for clinicians to actively intervene to improve public health. One approach is to test asymptomatic carriers of H. pylori and offer eradication therapy before irreversible changes occur. Such population-based intervention may theoretically eliminate gastric cancer. However, the problems of large samples, long-term follow-up, and ethical issues hinder the performance of randomized controlled trials to measure outcomes such as changes in the incidence of gastric cancer. 17 A good alternative to predict the late benefits of H. pylori eradication is cost-effectiveness analysis with computer simulation. This method allows researchers to calculate the incremental cost-effectiveness ratio, or the ratio of change in cost to change in effects, without the aforementioned limitations (Table 2) . Given a reduction in the initial transition rate (i.e. from normal mucosa to chronic active gastritis), our results suggest that eradication of H. pylori early in life can substantially reduce the risk of mortality and improve cost-effectiveness.
Clinical Trials of H. pylori Eradication to Prevent Gastric Cancer
Population-specific characteristics can confound the cost-effectiveness of H. pylori eradication. Therefore, the applicability of models should be confirmed in local clinical trials. The chemoprevention trials reported to date can be categorized according to differences in their target populations and outcome measures (Table 3) . [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Areas with high incidences of gastric cancer are East Asia and the Andean regions of South America, whereas North America, Northern Europe, Africa and Southeast Asia have relatively low rates. 1 It is reasonable that most population-based chemoprevention trials have been conducted in developing countries to increase the statistical power for detecting benefits of H. pylori eradication. One limitation is that most of the data supporting the efficacy of H. pylori eradication have been based on surrogate outcomes of histologic regression. If one considers the endpoint of a reduction in gastric cancer, only one randomized trial, conducted in China, has demonstrated risk reduction; the change was 37% after 7.5 years. 41 Although this result was not statistically significant, subgroup analysis showed a substantial reduction in the incidence of gastric cancer for subjects without premalignant changes (e.g. atrophic gastritis, intestinal metaplasia, and dysplasia). The results suggested a point of no return in that the benefits of H. pylori eradication might diminish at an advanced stage, when many types of molecular damage become irreversible.
For developed countries with a low risk of gastric cancer, attention has focused on saving costs related to managing dyspepsia. [34] [35] [36] [37] [38] [39] The second is corpus-predominant gastritis, which is associated with gastric atrophy, hypochlorhydria and an increased risk of gastric cancer. The third phenotype is antrum-predominant gastritis, which is associated with high secretion of gastric acid and an increased risk of duodenal ulcer disease. 51 This disease paradigm suggests that intragastric inflammatory responses are related to an interaction between host genetic makeup and bacterial virulence factors, one which determines the final outcomes after H. pylori infection. 52 Many researchers have focused on the role of strainspecific virulence factors for H. pylori-related disease, including cagA, vacA, iceA, babA, oipA and sabA. 14 At the same time, host genetic susceptibility may determine interindividual variation in the magnitude of cytokine responses and may contribute to the diversity of clinical outcomes. A series of pro-and anti-inflammatory cytokine polymorphisms are considered crucial to these outcomes. Potential candidate genes include those encoding interleukin (IL)-1β, IL-8, IL-10, tumor necrosis factor-4 and toll-like receptor 4. 53 Despite recent progress in identifying susceptible hosts, in determining bacterial genotypes, and in elucidating their association with advanced intragastric pathology, a geographical difference exists, and no conclusive data have been noted. Moreover, the underlying molecular mechanisms remain unclear.
Further in-depth studies in this field are warranted.
Concerns About Implementation on the Population Level
H. pylori eradication is the most practical means of preventing gastric cancer and peptic ulcer. However, some concerns must be addressed. First, the efficacy of population-based intervention for gastric cancer remains inconclusive in terms of long-term outcomes. Second, such an approach may be enormously costly and especially cumbersome for widespread implementation in developing countries. 54 67 As socioeconomic conditions improve in developing regions, declining incidence of H. pylori infection can reasonably be expected to lower the incidence of gastric cancer, similar to that which has happened in Western countries. Nevertheless, even if such a downward trend were to happen, it may take a long time to accomplish without active intervention in areas of highly prevalent infection.
Discussion and Conclusion
The discovery of a previously unappreciated microbial basis for peptic ulcer and gastric malignancy brings new challenges, namely, defining the etiologic effect of H. pylori infection and designing strategies for preventing these common gastroduodenal disorders. 68 Today, eradication of H. pylori is considered as the first-line treatment of peptic ulcer disease and MALT lymphoma. In 2005, the Nobel Prize for Medicine that was awarded to Marshall and Warren was a formal recognition of their discovery that many peptic ulcers were due to an infectious condition that can be cured with antibiotics. Elucidation of the central role of H. pylori in carcinogenesis has increased expectations in our ability to prevent gastric cancer by eradication of this bacterium. However, the effect of primary prevention in patients with premalignant gastric lesions and the long-term results of randomized clinical trials are still inconclusive. There is a clear need for studies with large numbers of patients, long follow-up, and careful control of the types of cancer and underlying gastric mucosal conditions. The current evidence does not enable us to accurately assess the benefits of universal testing and treatment. However, it is sufficient for targeted intervention, that is, identifying subjects who are susceptible to H. pylori-related diseases. Active screening of the general population in areas with high incidence of gastric cancer appears logical but is not yet evidence-based. The test-and-treat approach should be validated in randomized controlled trials and, thus, still has a long way to go.
